Teva Wins Approval for First Generic Lexapro for Depression
This article is for subscribers only.
Teva Pharmaceutical Industries Ltd. won U.S. approval to sell the first generic version of Lexapro for depression and anxiety.
Teva, the world’s largest generic drugmaker, will have 180 days to exclusively sell the copy of the medicine, the Food and Drug Administration said today in a statement. Lexapro is Forest Laboratories Inc.’s top-seller, with $2.3 billion in sales for the fiscal year ended in March 2011.